The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
Open accessAbstract
Selective inhibitors could help unveil the mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clinical benefits in cancer therapy. We profiled 10 clinical PARP inhibitors and commonly used research tools for their inhibition of multiple PARP enzymes. We also determined crystal structures of these compounds bound to PARP1 or PARP2. Veliparib and niraparib are selective inhibitors of PARP1 and PARP2; olaparib, rucaparib, and talazoparib are more potent inhibitors of PARP1 but are less selective. PJ34 and UPF1069 are broad PARP inhibitors; PJ34 inserts a flexible moiety into hydrophobic subpockets in various ADP-ribosyltransferases. XAV939 is a promiscuous tankyrase inhibitor and a potent inhibitor of PARP1 in vitro and in cells, whereas IWR1 and AZ-6102 are tankyrase selective. Our biochemical and structural analysis of PARP inhibitor potencies establishes a molecular basis for either selectivity or promiscuity and provides a benchmark for experimental design in assessment of PARP inhibitor effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,317
Scaling and assessment of data quality
Evans, P. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905036693 · Cited by 4,374
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Huang, S.-M. A., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009) · Nature · doi:10.1038/nature08356 · Cited by 2,037
Likelihood-enhanced fast translation functions
McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., & Read, R. J. (2005) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905001617 · Cited by 1,639
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
The cellular thermal shift assay for evaluating drug target interactions in cells
Jafari, R., Almqvist, H., Axelsson, H., Ignatushchenko, M., Lundbäck, T., Nordlund, P., & Molina, D. M. (2014) · Nature Protocols · doi:10.1038/nprot.2014.138 · Cited by 1,474
Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer
Chen, B., Dodge, M. E., Tang, W., Lu, J., Ma, Z., Fan, C.-W., Wei, S., Hao, W., Kilgore, J., Williams, N. S., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.137 · Cited by 1,383
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
The promise and peril of chemical probes
Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1867 · Cited by 839
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase
Amé, J.-C., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., Decker, P., Muller, S., Höger, T., Murcia, J. M.-D., & de Murcia, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17860 · Cited by 745
Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Langelier, M.-F., Planck, J. L., Roy, S., & Pascal, J. M. (2012) · Science · doi:10.1126/science.1216338 · Cited by 665
Menear, K. A., Adcock, C., Boulter, R., Cockcroft, X.-L., Copsey, L., Cranston, A., Dillon, K. J., Drzewiecki, J., Garman, S., Gomez, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001263 · Cited by 584
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
Kim, G., Ison, G., McKee, A. E., Zhang, H., Tang, S., Gwise, T., Sridhara, R., Lee, E., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 528
Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 479
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
Wahlberg, E., Karlberg, T., Kouznetsova, E., Markova, N., Macchiarulo, A., Thorsell, A.-G., Pol, E., Frostell, Å., Ekblad, T., Öncü, D., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2121 · Cited by 457
Self-citationPlummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, A., McHugh, P., Newell, D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 383
Frye, S. V. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.296 · Cited by 375
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Ferraris, D. V. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100012m · Cited by 363
JNK signalling in cancer: in need of new, smarter therapeutic targets
Bubici, C., & Papa, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12432 · Cited by 346
Substrate-Assisted Catalysis by PARP10 Limits Its Activity to Mono-ADP-Ribosylation
Kleine, H., Poreba, E., Lesniewicz, K., Hassa, P. O., Hottiger, M. O., Litchfield, D. W., Shilton, B. H., & Lüscher, B. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.08.009 · Cited by 338
Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
Li, M., & Yu, X. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.025 · Cited by 321
Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1
Eustermann, S., Wu, W.-F., Langelier, M.-F., Yang, J.-C., Easton, L. E., Riccio, A. A., Pascal, J. M., & Neuhaus, D. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.032 · Cited by 318
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4562 · Cited by 316
XDSAPP: a graphical user interface for the convenient processing of diffraction data using XDS
Krug, M., Weiss, M. S., Heinemann, U., & Mueller, U. (2012) · Journal of Applied Crystallography · doi:10.1107/s0021889812011715 · Cited by 306
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
Riffell, J. L., Lord, C. J., & Ashworth, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3868 · Cited by 285
Penning, T. D., Zhu, G.-D., Gandhi, V. B., Gong, J., Liu, X., Shi, Y., Klinghofer, V., Johnson, E. F., Donawho, C. K., Frost, D. J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801171j · Cited by 268
Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken.
Ruf, A., Mennissier de Murcia, J., de Murcia, G., & Schulz, G. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7481 · Cited by 241
Abdelkarim, G., Gertz, K., Harms, C., Katchanov, J., Dirnagl, U., Szabo, C., & Endres, M. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.7.3.255 · Cited by 241
Langelier, M.-F., Servent, K. M., Rogers, E. E., & Pascal, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708558200 · Cited by 204
Lehtiö, L., Chi, N., & Krauss, S. (2013) · The FEBS Journal · doi:10.1111/febs.12320 · Cited by 188
Camicia, R., Winkler, H. C., & Hassa, P. O. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0474-2 · Cited by 169
Ruf, A., Rolli, V., de Murcia, G., & Schulz, G. E. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1673 · Cited by 164
Papeo, G., Posteri, H., Borghi, D., Busel, A. A., Caprera, F., Casale, E., Ciomei, M., Cirla, A., Corti, E., D’Anello, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00680 · Cited by 147
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
Feng, F. Y.-C., Bono, J. S. D., Rubin, M. A., & Knudsen, K. E. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.016 · Cited by 141
Beck, C., Boehler, C., Guirouilh‐Barbat, J., Bonnet, M.-E., Illuzzi, G., Rondé, P., Gauthier, L., Magroun, N., Rajendran, A., López, B. S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku174 · Cited by 139
Structural Basis of Selective Inhibition of Human Tankyrases
Narwal, M., Venkannagari, H., & Lehtiö, L. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201510p · Cited by 137
PARP inhibitors in ovarian cancer
Ledermann, J. A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw094 · Cited by 132
Voronkov, A. E., Holsworth, D. D., Waaler, J., Wilson, S. R., Ekblad, B., Perdreau‐Dahl, H., Dinh, H., Drewes, G., Hopf, C., Morth, J. P., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4000566 · Cited by 121
Structural Basis for the Interaction between Tankyrase-2 and a Potent Wnt-Signaling Inhibitor
Karlberg, T., Markova, N., Johansson, I., Hammarström, M., Schutz, P., Weigelt, J., & Schuler, H. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100249w · Cited by 117
Self-citationStructural Basis for Inhibitor Specificity in Human Poly(ADP-ribose) Polymerase-3
Lehtiö, L., Jemth, A., Collins, R., Loseva, O., Johansson, A., Markova, N., Hammarström, M., Flores, A., Holmberg-Schiavone, L., Weigelt, J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900052j · Cited by 100
Self-citationLangelier, M.-F., Planck, J. L., Servent, K. M., & Pascal, J. M. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-270-0_13 · Cited by 98
Identification of potential active-site residues in the human poly(ADP-ribose) polymerase.
Simonin, F., Poch, O., Delarue, M. H., & de MURCIA, G. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52907-0 · Cited by 91
Crystal Structure of the Catalytic Domain of Human PARP2 in Complex with PARP Inhibitor ABT-888
Karlberg, T., Hammarström, M., Schutz, P., Svensson, L., & Schuler, H. (2010) · Biochemistry · doi:10.1021/bi902079y · Cited by 88
Self-citationPaola, S. D., Micaroni, M., Tullio, G. D., Buccione, R., & Girolamo, M. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037352 · Cited by 87
Karlberg, T., Klepsch, M. M., Thorsell, A. G., Andersson, C. D., Linusson, A., & Schuler, H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.630160 · Cited by 86
Self-citationPoly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer
Kwan, T. T., Bock, F. J., & Chang, P. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.002 · Cited by 85
The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair
Fenton, A. L., Shirodkar, P., Macrae, C. J., Meng, L., & Koch, C. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt134 · Cited by 85
PARP inhibitors: polypharmacology versus selective inhibition
Ekblad, T., Camaioni, E., Schuler, H., & Macchiarulo, A. (2013) · FEBS Journal · doi:10.1111/febs.12298 · Cited by 82
Self-citationShultz, M. D., Kirby, C. A., Stams, T., Chin, D. N., Blank, J., Charlat, O., Cheng, H., Cheung, A. K., Cong, F., Feng, Y., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2011222 · Cited by 69
Johannes, J. W., Almeida, L., Barlaam, B. C., Boriack‐Sjodin, P. A., Casella, R., Croft, R. A., Dishington, A. P., Gingipalli, L., Gu, C., Hawkins, J. L., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5003663 · Cited by 69
Oncology Drug Discovery: Planning a Turnaround
Toniatti, C., Jones, P. S., Graham, H., Pagliara, B., & Draetta, G. F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0452 · Cited by 59
Aoyagi-Scharber, M., Gardberg, A. S., Yip, B. K., Wang, B., Shen, Y., & Fitzpatrick, P. (2014) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x14015088 · Cited by 57
Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939
Kirby, C. A., Cheung, A. K., Fazal, A., Shultz, M. D., & Stams, T. (2012) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309111051219 · Cited by 52
Sunderland, P., Woon, E. C. Y., Dhami, A., Bergin, A. B., Mahon, M. F., Wood, P. J., Jones, L., Tully, S., Lloyd, M. D., Thompson, A. S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1010918 · Cited by 51
Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors
Haikarainen, T., Narwal, M., Joensuu, P., & Lehtiö, L. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400292s · Cited by 51
Moroni, F., Formentini, L., Gerace, E., Camaioni, E., Pellegrini-Giampietro, D. E., Chiarugi, A., & Pellicciari, R. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00232.x · Cited by 46
Yao, H., Ji, M., Zhu, Z., Zhou, J., Cao, R., Chen, X., & Xu, B. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.071 · Cited by 44
Function and Regulation of the Mono-ADP-Ribosyltransferase ARTD10
Kaufmann, M., Feijs, K. L. H., & Lüscher, B. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_379 · Cited by 35
Karlberg, T., Thorsell, A. G., Kallas, Å., & Schuler, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.379289 · Cited by 26
Self-citationPhotoaffinity labelling of human poly(ADP-ribose) polymerase catalytic domain
Kim, H., Jacobson, M. K., Rolli, V., Murcia, J. M., Reinbolt, J., Simonin, F., Ruf, A., Schulz, G. E., & de MURCIA, G. (1997) · Biochemical Journal · doi:10.1042/bj3220469 · Cited by 20
Papeo, G., Avanzi, N. R., Bettoni, S., Leone, A., Paolucci, M., Perego, R., Quartieri, F., Sirtori, F. R., Thieffine, S., Montagnoli, A., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114538319 · Cited by 20
Cited by
PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
Gupte, R., Liu, Z., & Kraus, W. L. (2017) · Genes & Development · doi:10.1101/gad.291518.116 · Cited by 681
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabo, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 556
Establishment of porcine and human expanded potential stem cells
Gao, X., Nowak-Imialek, M., Chen, X., Chen, D., Herrmann, D., Ruan, D., Chen, A. C. H., Eckersley-Maslin, M. A., Ahmad, S., Lee, Y. L., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0333-2 · Cited by 389
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
Metadata
- Authors
- Thorsell, A.-G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Trésaugues, L., Moche, M., Cohen, M. S., & Schüler, H.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-12-21
- Volume
- 60
- Issue
- 4
- Pages
- 1262-1271
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2557717244
- Cited by
- 358
- References
- 68
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.